Eastern Bank Boosts Stock Holdings in Johnson & Johnson $JNJ

Eastern Bank increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 105.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 299,306 shares of the company's stock after acquiring an additional 153,938 shares during the period. Johnson & Johnson makes up approximately 1.2% of Eastern Bank's investment portfolio, making the stock its 24th biggest position. Eastern Bank's holdings in Johnson & Johnson were worth $79,238,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Outlook Capital Management LLC bought a new stake in Johnson & Johnson in the second quarter worth $28,000. Matrix Trust Co increased its position in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after acquiring an additional 54 shares during the last quarter. Hyposwiss Advisors SA purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $42,000. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $43,000. Finally, Polaris Financial Partners purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth about $56,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.8%

Shares of Johnson & Johnson stock traded down $2.07 on Monday, hitting $253.96. 3,711,162 shares of the company traded hands, compared to its average volume of 7,973,521. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $612.02 billion, a PE ratio of 29.43, a PEG ratio of 2.52 and a beta of 0.21. The stock's 50 day moving average price is $266.37 and its 200-day moving average price is $248.40. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson's quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts predict that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is presently 62.11%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 87,569 shares of company stock worth $23,064,544 in the last three months. Corporate insiders own 0.16% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Citigroup reissued a "buy" rating on shares of Johnson & Johnson in a research report on Monday. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. The Goldman Sachs Group reissued a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Finally, JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $275.87.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.